KCTD9 Activators
KCTD9 Activators are an array of chemical compounds that serve to enhance the functional activity of KCTD9 through the modulation of various cellular signaling pathways. Forskolin and 8-Br-cAMP, by increasing intracellular cAMP levels, lead to the activation of protein kinase A (PKA), which subsequently may phosphorylate proteins that interact with or regulate KCTD9, thereby enhancing its activity. IBMX also raises cAMP levels by inhibiting phosphodiesterases, similarly promoting PKA activity. PMA, as a PKC activator, could modify KCTD9's activity indirectly by influencing downstream proteins or altering the cellular context in which KCTD9 operates. A23187, by increasing intracellular calcium, could potentiate KCTD9's function within calcium signaling pathways. Lithium chloride's inhibition of GSK-3 may indirectly enhance KCTD9 activity by affecting the stability and function of proteins within KCTD9-associated pathways, while okadaic acid's inhibition of protein phosphatases PP1 and PP2A could lead to an upsurge in protein phosphorylation, potentially impacting KCTD9.
Furthermore, roscovitine's selective inhibition of CDKs may have downstream effects that indirectly increase KCTD9 activity due to alterations in cell cycle-associated signaling pathways. Intriguingly, chelerythrine and Bisindolylmaleimide I, both selective PKC inhibitors, could prompt the activation of alternative pathways that compensate for PKC inhibition, which might result in the enhancement of KCTD9 activity. The peptide hormones vasopressin and oxytocin, through their receptor-mediated actions, elevate intracellular calcium levels and could thereby activate signaling pathways potentially involving KCTD9. Collectively, these activators, through their targeted biochemical actions, forge a conducive environment for the enhancement of KCTD9-mediated functions within the cell, by modulating signaling pathways that intersect with the regulatory mechanisms of KCTD9.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin raises intracellular cAMP levels, which can lead to the activation of protein kinase A (PKA). PKA can phosphorylate target proteins, potentially including KCTD9 or its associated proteins, therefore enhancing KCTD9's activity in its role within cellular signaling pathways. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX (3-Isobutyl-1-methylxanthine) is a non-specific inhibitor of phosphodiesterases, leading to an increase in cAMP by preventing its breakdown. This elevation of cAMP could enhance PKA activity, thereby possibly increasing the functional activity of KCTD9 through phosphorylation mechanisms. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC). PKC activation can influence various cellular functions and may indirectly enhance the activity of KCTD9 by modifying downstream targets or altering the cellular environment in which KCTD9 functions. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 increases intracellular calcium levels, which can activate calcium-dependent protein kinases. KCTD9 activity could be enhanced due to changes in the calcium signaling pathways, as calcium acts as a second messenger in many cellular processes. | ||||||
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $108.00 $169.00 $295.00 $561.00 $835.00 | 2 | |
8-Bromo-cAMP is a cell-permeable analog of cAMP that resists degradation by phosphodiesterases. It can activate PKA similarly to cAMP, potentially enhancing KCTD9 activity through phosphorylation events. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride inhibits glycogen synthase kinase-3 (GSK-3). Inhibition of GSK-3 could stabilize proteins and indirectly enhance KCTD9 activity through the modification of signaling pathways where GSK-3 is a negative regulator. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is an inhibitor of protein phosphatases PP1 and PP2A, leading to increased phosphorylation levels of proteins. This may enhance KCTD9 activity indirectly by affecting the phosphorylation state of proteins within KCTD9's signaling pathways. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine is a selective inhibitor of cyclin-dependent kinases (CDKs). By inhibiting CDKs, it could alter the cell cycle and potentially increase KCTD9 activity as a downstream effect of changes in cell cycle-related signaling. | ||||||
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
Chelerythrine is a selective inhibitor of PKC. While it is typically an inhibitor, the selective modulation of PKC isoforms can lead to compensatory activation of alternative pathways that could enhance KCTD9 activity indirectly. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is another selective inhibitor of PKC. Its inhibitory effects on specific PKC isoforms might lead to the activation of compensatory pathways that enhance KCTD9 activity. | ||||||